Ipsen.com - SEO Checker

¡Registrarme gratis! Exportar PDF
Visión general del análisis SEO
Metadatos
80% 
Calidad de la página
91% 
Estructura
75% 
Enlazado
33% 
Servidor
87% 
Factores externos
100% 
Puntuación SEO
Tiempo de carga
8,98 s
Tamaño HTML
149,50 kB
Palabras
1374
Medios
49
Cantidad de enlaces
140 internos / 7 externos

Lista de tareas pendientes para mejorar tu SEO

Metadatos

Título
(Extremadamente importante)
Ipsen Global - A Biopharmaceutical Company | Innovation for Patient Care
Con 664 píxeles, el título de esta página es demasiado largo. Optimizar el título
No se repite ninguna palabra en el título.
Meta descripción
(Extremadamente importante)
Ipsen is a global biopharmaceutical company focused on innovation and specialty care to improve the lives of patients around the world.
La longitud de la meta descripción es óptima (835 píxeles de una longitud máxima de 1000 píxeles).
Rastreabilidad
(Extremadamente importante)
No se detectan problemas para acceder al sitio web.
Redirección canónica
(Importante)
https://www.ipsen.com/
La página tiene una redirección canónica correcta.
Idioma
(Poco importante)
Idioma reconocido automáticamente en el contenido: en
Idioma declarado en el código HTML: en-us
Ubicación geográfica del servidor: Estados Unidos de América
El idioma ha sido correctamente declarado en el código HTML: en-us.
Enlaces Alternate/Hreflang
(Poco importante)
No se identifica ningún error en los enlaces alternate/hreflang.
Otras Metaetiquetas
(Poco importante)
No se detecta ninguna metaetiqueta de paginación rel next en la página.
No se detecta ninguna metaetiqueta de paginación rel prev en la página.
Dominio
(Poco importante)
El dominio no es un subdominio.
La longitud del nombre del dominio es buena.
El dominio no contiene caracteres especiales.
URL de la página
(Poco importante)
No se detecta ningún parámetro dinámico en la URL.
No se detecta ningún ID de sesión en la URL.
La URL no contiene demasiados subdirectorios.
Codificación de caracteres
(Poco importante)
La codificación de caracteres (UTF-8) ha sido declarada correctamente.
Doctype
(Deseable)
La etiqueta doctype HTML 5 está configurada correctamente.
La declaración del doctype se ubica al inicio del código HTML.
Favicon
(Deseable)
El favicon está enlazado correctamente.

Metaetiquetas

NombreValor
viewportwidth=device-width, initial-scale=1
robotsindex, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1
descriptionIpsen is a global biopharmaceutical company focused on innovation and specialty care to improve the lives of patients around the world.
google-site-verificationjgzhVZarP1499LBpCYuY60W5QzkLY9-_hcm5_6ZQ0G4
generatorWPML ver:4.6.11 stt:1,4;
msapplication-TileImagehttps://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/04/19135239/favicon.png
article:modified_time2024-07-31T18:36:30+00:00
langen-us
twitter:cardsummary_large_image
twitter:site@ipsengroup
og:localeen_US
og:typewebsite
og:titleIpsen Global - A Biopharmaceutical Company | Innovation for Patient Care
og:descriptionIpsen is a global biopharmaceutical company focused on innovation and specialty care to improve the lives of patients around the world.
og:urlhttps://www.ipsen.com/
og:site_nameGlobal
X-UA-CompatibleIE=edge
charsetUTF-8

¡Analiza ya gratis hasta 1.000 páginas de ipsen.com!

Registrarme Gratis
Puedes usar la suscripción Básica por tiempo ilimitado.

Calidad de la página

Contenido
(Extremadamente importante)
La cantidad media de palabras por frase es elevada: 25.94 palabras.
El número total de palabras en la página es bueno: 1374 palabras.
Un 31.3% del contenido está constituido por palabras vacías.
Las palabras clave del título también se repiten en el texto del cuerpo.
La página contiene un listado, lo que indica una buena estructuración del contenido.
Se han encontrado 30 párrafos en esta página.
El contenido en formato texto de esta página es óptimo.
No se detecta ningún placeholder de texto ni imagen.
No se detecta contenido duplicado.
Frames
(Extremadamente importante)
Esta página no utiliza ningún frameset.
Optimización para móviles
(Poco importante)
El valor de la etiqueta viewport es correcto: (width=device-width, initial-scale=1).
Al menos un icono de Apple-Touch ha sido especificado.
Etiquetas Bold y Strong
(Poco importante)
El uso de etiquetas de negritas en esta página es óptimo. Te recomendamos emplear hasta 27 etiquetas de negritas en una página.
Optimización de imágenes
(Poco importante)
No se detecta ninguna descripción del atributo ALT en 8 imágenes. El contenido de los atributos ALT también es evaluado como texto por los buscadores y es muy importante para la búsqueda de imágenes.
Redes Sociales
(Deseable)
Esta página apenas ofrece posibilidades de compartir el contenido en redes sociales. Con la integración de widgets puedes conseguir que tus contenidos se popularicen en redes.
Etiquetas markup adicionales
(Deseable)
No se detecta ninguna etiqueta markup (de Schema.org) adicional.
HTTPS
(Poco importante)
El sitio utiliza HTTPS para transferir datos de forma segura.
Todos los archivos incluidos se transfieren a través de HTTPS.

Lista de medios

URLAtributo ALTTítulo
...12/07162335/Latest_Ipsen-logo_168x48.svgHome
...t/themes/ipsen-main/dist/images/down.pngarrow_downarrow_down
.../uploads/2024/05/17174619/TL-graphic.jpgFeatured ImageFeatured Image
...t/themes/ipsen-main/dist/images/down.pngarrow_downarrow_down
...2170035/Boulogne-France-img-15-S-1-1.pngFeatured ImageFeatured Image
...120943/Image-3_Resize_400x240pix_LD.jpegFeatured ImageFeatured Image
...t/themes/ipsen-main/dist/images/down.pngarrow_downarrow_down
...t/themes/ipsen-main/dist/images/down.pngarrow_downarrow_down
...themes/ipsen-main/dist/images/Global.pngGlobalGlobal
...t/themes/ipsen-main/dist/images/down.pngarrow_downarrow_down
...t/themes/ipsen-main/dist/images/down.pngarrow_downarrow_down
...t/themes/ipsen-main/dist/images/down.pngarrow_downarrow_down
...t/themes/ipsen-main/dist/images/down.pngarrow_downarrow_down
...20249/Image-2_Resize_1920x720pix_LD.jpegHero Banner Video ImageHero Banner Video Image
...th-road-UK-img-03-none_R_1980x720pix.jpgHero BannerHero Banner
...rtnering_Ipsen-com_1920x720pix_1_OK.jpegHero BannerHero Banner
...dule-1_Carrousel_R-and-D_1920x720pix.jpgHero BannerHero Banner
...023/04/19104246/02_WhatWeDo_DSA01946.pngWHAT WE DOWHAT WE DO
...ads/2023/04/19110109/03_CEO_image1v2.pngAuthor ImageAuthor Image
...t/uploads/2023/05/28120505/PR_final.jpegCarece de atributo ALTIpsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat)...
...t/uploads/2023/05/28120505/PR_final.jpegCarece de atributo ALTIpsen delivers strong results in the first half of 2024, progresses on launches and upgrades...
...t/uploads/2023/05/28120505/PR_final.jpegCarece de atributo ALTIpsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the...
...t/uploads/2023/05/28120505/PR_final.jpegCarece de atributo ALTIpsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
...t/uploads/2023/05/28120505/PR_final.jpegCarece de atributo ALTIpsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary...
...t/uploads/2023/05/28120505/PR_final.jpegCarece de atributo ALTIpsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary...
.../uploads/2024/05/17174619/TL-graphic.jpgCarece de atributo ALTOur 2023 Integrated Annual Report is live!
...d-Photos-Overlapped_181204-324_RONNY.pngImage infoImage info
...Overlapped_20201011_6792-HD_LIU-GANG.pngImage infoImage info
...d-Photos-Overlapped_526A1119_STEPHEN.pngImage infoImage info
...121558/Image-4_Resize_400x240pix_LD.jpegImage infoImage info
...-spastic-cerebral-palsy_237-HD_MISHA.pngImage infoImage info
...3583_Text-and-Photos-Regular-Right-1.pngRESPONSIBILITYRESPONSIBILITY
...ther_Ipsen-com_1082x620pix_VISUAL_1.jpegWinning Together at Ipsen Winning Together at Ipsen 
...2170035/Boulogne-France-img-15-S-1-1.pngStrong growth and expanding pipeline in the first half of 2024 drive raised guidanceStrong growth and expanding pipeline in the first half of 2024 drive raised guidance
...2024/07/12165338/Ipsen.com-Thumbnail.pngHow physicians can help empower people living with Primary Biliary Cholangitis How physicians can help empower people living with Primary Biliary Cholangitis 
...2170035/Boulogne-France-img-15-S-1-1.pngFinancial results for the first half of 2024Financial results for the first half of 2024
...ciences-Summit_Ipsen-com_1082x620pix.jpgIpsen shines at ESG Life Sciences Summit Europe 2024 Ipsen shines at ESG Life Sciences Summit Europe 2024 
...06_Pride-Month_Ipsen-com_1082x620pix.jpgSpectra ERG Celebrates its First Anniversary Supporting the LGBTQIA+ Community at Ipsen Spectra ERG Celebrates its First Anniversary Supporting the LGBTQIA+ Community at Ipsen 
...7084032/Ipsen.com-Profile-2_1082x620.jpgThe importance of personalized care to empower patients with PBC The importance of personalized care to empower patients with PBC 
.../uploads/2024/05/17174619/TL-graphic.jpgOur 2023 Integrated Annual Report is live!Our 2023 Integrated Annual Report is live!
...C-Action-Plan-website-image_1082x620.jpgTogether, we can improve the lives of people living with kidney cancerTogether, we can improve the lives of people living with kidney cancer
...5/31080358/Ipsen-Environment_700x420.jpgIpsen’s Commitment to Biodiversity  Ipsen’s Commitment to Biodiversity  
...12/07162335/Latest_Ipsen-logo_168x48.svgCarece de atributo ALT
...nt/uploads/2023/04/19050858/LinkedIn.pngLinkedInLinkedIn
...ads/2023/08/02083550/TWITTER_FILL_1x.pngTwitterTwitter
...nt/uploads/2023/04/19053326/Facebook.pngFacebookFacebook
...t/uploads/2023/04/19053437/Instagram.pngInstagramInstagram
...t/uploads/2023/04/19053540/Youtube-1.pngYoutubeYoutube

Estructura de la página

Encabezado H1
(Extremadamente importante)
No se ha detectado ningún encabezado H1.
Encabezados
(Importante)
En la estructura de los encabezados H faltan uno o varios niveles.
Algunos encabezados H están vacíos.

Estructura de los encabezados

Jerarquía de encabezadosContenido
H2 Focus. Together. For patients and society.
H2 Ipsen Way of Being
H2 Partnering for success
H2 Guided by patient outcomes
H2 Encabezado vacío
H2 The latest highlights from Ipsen
H2 How Ipsen helps
H2 Careers at Ipsen
H2 Discover trending stories
H3 Putting patients at the heart of our work
H3 Encabezado vacío
Algunos textos ancla son demasiado largos.
Algunos textos ancla se repiten más de una vez en varios enlaces.
14 enlaces cerecen de un texto ancla.
Hay 1 links con un texto ancla que no es suficientemente relevante.
La cantidad de enlaces internos es adecuada.
Ningún enlace interno contiene parámetros dinámicos.
Hay 7 enlaces externos en esta página.

Enlaces detectados en esta página

EnlacePropiedadesTexto ancla
https://www.ipsen.com/Subdominio IMG-ALT Home
/press-release/Subdominio Press Releases
/media-statements/Subdominio Media Statements
/media-library/Subdominio Media Library
/general/our-2023-integrated-a...Subdominio Our 2023 Integrated Annual Report is live!
https://www.ipsen.com/investors/Subdominio Investors
/investors/financial-results/Subdominio Financial Results
/investors/corporate-news/Subdominio Corporate News
/investors/financial-calendar/Subdominio Financial Calendar
/investors/investor-events/Subdominio Investor Events
/investors/reports-and-accounts/Subdominio Reports and Accounts
/investors/regulated-information/Subdominio Regulated Information
/general/financial-results-for...Subdominio Financial results for the first half of 2024
/shareholdersmeet/2024-annual-...Subdominio 2024 Annual General Meeting
https://www.ipsen.com/partnering/Subdominio Partnering
https://www.ipsen.com/careers/Subdominio Careers
/careers/working-at-ipsen/Subdominio Working at Ipsen
/careers/our-culture/Subdominio Culture
https://www.ipsen.com/Subdominio English  EN
https://www.ipsen.com/fr/Subdominio Français  FR
https://www.ipsen.com/Subdominio EnglishEN
https://www.ipsen.com/fr/Subdominio FrançaisFR
https://www.ipsen.com/Subdominio Global
https://www.ipsen.com/Subdominio EN
https://www.ipsen.com/frSubdominio FR
/annualreportSubdominio Annual Report
/annualreportSubdominio Texto duplicado EN
/annualreport/frSubdominio Texto duplicado FR
https://www.ipsen.com/us/Nueva ventana Subdominio United States
https://www.ipsen.com/brazil/Nueva ventana Subdominio Brazil
https://www.ipsen.com/canadaen/Nueva ventana Subdominio Canada EN
https://www.ipsen.com/canadafr/Nueva ventana Subdominio Canada FR
https://www.ipsen.com/aus/Nueva ventana Subdominio Australia
https://www.ipsen.cn/Nueva ventana Externo Subdominio China
https://www.ipsen.com/singapore/Nueva ventana Subdominio Singapore
https://www.ipsen.com/korea/Nueva ventana Subdominio South Korea
https://www.ipsen.com/japan/Nueva ventana Subdominio Japan
https://www.ipsen.com/be/Nueva ventana Subdominio Belgium
https://www.ipsen.com/ukraine/Nueva ventana Subdominio Ukraine
https://www.ipsen.com/uk-ireland/Nueva ventana Subdominio UK
https://www.ipsen.com/germany/Nueva ventana Subdominio Germany
https://www.ipsen.com/france/Nueva ventana Subdominio France
https://www.ipsennordic.com/Nueva ventana Externo Subdominio Nordics
https://www.ipsen.com/greece/Nueva ventana Subdominio Greece
https://www.ipsen.com/it/Nueva ventana Subdominio Italy
/netherlands/Nueva ventana Subdominio Netherlands
https://www.ipsen.com/spain/Nueva ventana Subdominio Spain
https://www.ipsen.com/poland/Nueva ventana Subdominio Poland
https://www.ipsen.com/russia/Nueva ventana Subdominio Russia
https://www.ipsen.com/czc/Nueva ventana Subdominio Czech Republic
/switzerland/Nueva ventana Subdominio Switzerland
https://www.ipsen.com/Subdominio Texto duplicado Home
https://www.ipsen.com/company/Subdominio Company
/company/leadership-team/Subdominio Leadership
/company/history/Subdominio History
/company/foundation-ipsen/Subdominio Fondation Ipsen
https://www.ipsen.com/oncology/Subdominio Oncology
/rare-diseases/Subdominio Rare Disease
/neuroscience/Subdominio Neuroscience
/our-products/Subdominio Products
/research-and-development/Subdominio R&D
https://www.ipsen.com/pipeline/Subdominio Pipeline
/clinical-trials/Subdominio Clinical Trials
/responsibility/Subdominio Responsibility
/responsibility/environment/Subdominio Environment
/responsibility/patients/Subdominio Patients
/responsibility/people/Subdominio People
/responsibility/governance/Subdominio Governance
/responsibility/our-standards/Subdominio Our Standards
https://www.ipsen.com/patients/Subdominio Texto duplicado Patients
/patients/together-for-oncology/Subdominio Together for Oncology
/patients/together-for-rare-di...Subdominio Together for Rare Disease
/patients/together-for-neurosc...Subdominio Together for Neuroscience
/patients/lay-summaries/Subdominio Lay Summaries
/patients/collaborate-with-us/Subdominio Collaborate with us
https://www.ipsen.com/stories/Subdominio Stories
https://www.ipsen.com/company/Subdominio Learn about our strategy
https://www.ipsen.com/careers/Subdominio Texto ancla no relevante
Read more
https://www.ipsen.com/partnering/Subdominio Find out more
/research-and-development/Subdominio Learn more
/research-and-development/Subdominio Texto duplicado Learn more
/press-releases/ipsen-receives...Subdominio Sin texto
/press-releases/ipsen-receives...Subdominio Sin texto
/press-releases/ipsen-receives...Subdominio Rare Diseases – 26 July 2024 Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat)…
/press-releases/ipsen-delivers...Subdominio Sin texto
/press-releases/ipsen-delivers...Subdominio Sin texto
/press-releases/ipsen-delivers...Subdominio Financial – 25 July 2024 Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades…
/press-releases/ipsen-and-day-...Subdominio Sin texto
/press-releases/ipsen-and-day-...Subdominio Sin texto
/press-releases/ipsen-and-day-...Subdominio Partnering – 25 July 2024 Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the…
/press-releases/ipsen-and-fore...Subdominio Sin texto
/press-releases/ipsen-and-fore...Subdominio Sin texto
/press-releases/ipsen-and-fore...Subdominio Partnering – 11 July 2024 Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class pote...
/press-releases/ipsens-iqirvo-...Subdominio Sin texto
/press-releases/ipsens-iqirvo-...Subdominio Sin texto
/press-releases/ipsens-iqirvo-...Subdominio Rare Diseases – 10 June 2024 Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary…
/press-releases/ipsen-presents...Subdominio Sin texto
/press-releases/ipsen-presents...Subdominio Sin texto
/press-releases/ipsen-presents...Subdominio Rare Diseases – 05 June 2024 Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary…
/general/our-2023-integrated-a...Subdominio Sin texto
/general/our-2023-integrated-a...Subdominio Sin texto
/general/our-2023-integrated-a...Subdominio General – 31 May 2024 Our 2023 Integrated Annual Report is live!
https://www.ipsen.com/oncology/Oncology Ipsen has been working in oncology since 1986, and now has a portfolio that includes treatments for neuroendocrine tumor (NETs), and cancers of the ...
/rare-diseases/Rare Disease Ninety-four percent of rare medical conditions still have no treatment. We are committed to finding treatments for extremely rare bone diseases ...
/neuroscience/Neuroscience Ipsen draws on 30 years of expertise in toxins and neuroscience research to support children and adults suffering from debilitating and degenera...
https://www.ipsen.com/patients/Subdominio Texto duplicado Learn more
/responsibility/Subdominio Texto duplicado Learn more
https://www.ipsen.com/careers/Subdominio Explore careers at Ipsen
/responsibility/winning-togeth...Subdominio IMG-ALT Winning Together at Ipsen
A-TITLE Winning Together at Ipsen
/responsibility/winning-togeth...Subdominio Texto duplicado Winning Together at Ipsen
A-TITLE Winning Together at Ipsen
/financial-results/strong-grow...Subdominio IMG-ALT Strong growth and expanding pipeline in the first half of 2024 drive raised guidance
A-TITLE Strong growth and expanding pipeline in the first half of 2024 drive raised guidance
/financial-results/strong-grow...Subdominio Texto duplicado Strong growth and expanding pipeline in the first half of 2024 drive raised guidance
A-TITLE Strong growth and expanding pipeline in the first half of 2024 drive raised guidance
/rare-diseases/how-physicians-...Subdominio IMG-ALT How physicians can help empower people living with Primary Biliary Cholangitis
A-TITLE How physicians can help empower people living with Primary Biliary Cholangitis
/rare-diseases/how-physicians-...Subdominio Texto duplicado How physicians can help empower people living with Primary Biliary Cholangitis
A-TITLE How physicians can help empower people living with Primary Biliary Cholangitis
/general/financial-results-for...Subdominio Texto duplicado IMG-ALT Financial results for the first half of 2024
A-TITLE Financial results for the first half of 2024
/general/financial-results-for...Subdominio Texto duplicado Financial results for the first half of 2024
A-TITLE Financial results for the first half of 2024
/responsibility/ipsen-shines-a...Subdominio IMG-ALT Ipsen shines at ESG Life Sciences Summit Europe 2024
A-TITLE Ipsen shines at ESG Life Sciences Summit Europe 2024
/responsibility/ipsen-shines-a...Subdominio Texto duplicado Ipsen shines at ESG Life Sciences Summit Europe 2024
A-TITLE Ipsen shines at ESG Life Sciences Summit Europe 2024
/culture/spectra-erg-celebrate...Subdominio IMG-ALT Spectra ERG Celebrates its First Anniversary Supporting the LGBTQIA+ Community at Ipsen
A-TITLE Spectra ERG Celebrates its First Anniversary Supporting the LGBTQIA+ Community at Ipsen
/culture/spectra-erg-celebrate...Subdominio Texto duplicado Spectra ERG Celebrates its First Anniversary Supporting the LGBTQIA+ Community at Ipsen
A-TITLE Spectra ERG Celebrates its First Anniversary Supporting the LGBTQIA+ Community at Ipsen
/rare-diseases/the-importance-...Subdominio IMG-ALT The importance of personalized care to empower patients with PBC
A-TITLE The importance of personalized care to empower patients with PBC
/rare-diseases/the-importance-...Subdominio Texto duplicado The importance of personalized care to empower patients with PBC
A-TITLE The importance of personalized care to empower patients with PBC
/general/our-2023-integrated-a...Subdominio Texto duplicado IMG-ALT Our 2023 Integrated Annual Report is live!
A-TITLE Our 2023 Integrated Annual Report is live!
/general/our-2023-integrated-a...Subdominio Texto duplicado Our 2023 Integrated Annual Report is live!
A-TITLE Our 2023 Integrated Annual Report is live!
/oncology/together-we-can-impr...Subdominio IMG-ALT Together, we can improve the lives of people living with kidney cancer
A-TITLE Together, we can improve the lives of people living with kidney cancer
/oncology/together-we-can-impr...Subdominio Texto duplicado Together, we can improve the lives of people living with kidney cancer
A-TITLE Together, we can improve the lives of people living with kidney cancer
/responsibility/ipsens-commitm...Subdominio IMG-ALT Ipsen’s Commitment to Biodiversity
A-TITLE Ipsen’s Commitment to Biodiversity
/responsibility/ipsens-commitm...Subdominio Texto duplicado Ipsen’s Commitment to Biodiversity
A-TITLE Ipsen’s Commitment to Biodiversity
https://www.ipsen.com/stories/Subdominio View all stories
A-TITLE View all stories
/press-release/Subdominio Media
https://www.ipsen.com/investors/Subdominio Texto duplicado Investors
https://www.ipsen.com/partnering/Subdominio Texto duplicado Partnering
https://www.ipsen.com/careers/Subdominio Texto duplicado Careers
https://www.ipsen.com/company/Subdominio Texto duplicado Company
/responsibility/Subdominio Texto duplicado Responsibility
https://www.ipsen.com/patients/Subdominio Texto duplicado Patients
https://www.ipsen.com/stories/Subdominio Texto duplicado Stories
/annualreport/Nueva ventana Subdominio Texto duplicado Annual Report
https://www.ipsen.com/contact-us/Subdominio Contact us
https://www.linkedin.com/compa...Nueva ventana Externo Subdominio IMG-ALT LinkedIn
https://twitter.com/ipsengroupNueva ventana Externo IMG-ALT Twitter
https://www.facebook.com/Ipsen...Nueva ventana Externo Subdominio IMG-ALT Facebook
https://www.instagram.com/ipse...Nueva ventana Externo Subdominio IMG-ALT Instagram
https://www.youtube.com/IpsenB...Nueva ventana Externo Subdominio IMG-ALT Youtube
/terms-and-conditions/Subdominio Terms and Conditions
/cookie-policy/Subdominio Cookie Policy
/global-privacy-policy/Subdominio Global Privacy Policy

Configuración del servidor

Redirecciones HTTP
(Extremadamente importante)
Esta página redirige a "https://www.ipsen.com/".
Cabecera HTTP
(Importante)
La versión del servidor web se especifica dentro de la cabecera HTTP.
La cabecera X-Powered-by no se envía en la cabecera de la página.
Esta página utiliza GZip para la transmisión de datos comprimidos.
Rendimiento
(Poco importante)
Con 8,98 segundos, el tiempo de respuesta de la página es superior al límite recomendado de 0,4 segundos. Un tiempo de respuesta elevado ralentiza innecesariamente el rastreo de los buscadores y propicia una mala experiencia de uso.
Una red de distribución de contenidos como Google Hosted Libraries puede ahorrarte ancho de banda para los archivos JQuery.
Una red de distribución de contenidos como Bootstrap CDN puede ahorrarte ancho de banda al integrar componentes fron-end de las librerias Bootstrap.
El tamaño HTML de la página es adecuado: 150 kB.

Cabecera HTTP

NombreValor
content-typetext/html; charset=UTF-8
content-length26140
access-control-allow-origin*
cache-controlmax-age=0
content-encodinggzip
dateSun, 18 Aug 2024 13:00:48 GMT
expiresSun, 18 Aug 2024 13:00:48 GMT
link<https://www.ipsen.com/wp-json/>; rel="https://api.w.org/", <https://www.ipsen.com/wp-json/wp/v2/pages/17>; rel="alternate"; title="JSON"; type="application/json", <https://www.ipsen.com/>; rel=shortlink
serverApache/2.4.59 () OpenSSL/1.0.2k-fips
set-cookie166 Caracteres
varyAccept-Encoding
x-cacheMiss from cloudfront
via1.1 5626bf35345f32d3e58fb8d33ec4d966.cloudfront.net (CloudFront)
x-amz-cf-popFRA56-P3
x-amz-cf-id3pwa5NIPp5bpw_4Wffga520qnqhJmdgtPmprrBxF6EHrJkduF6dzKQ==
statuscode200
http_versionHTTP/2

Factores externos

Listas negras
(Deseable)
Esta página no está clasificada como “contenido para adultos”.
Wikipedia enlaza esta página en sus fuentes.
Esta página recibe enlaces de calidad de otros sitios web.
Esta página recibe backlinks de 2.708 dominios de referencia.
Esta página recibe un total de 463.737 backlinks.
Esta página recibe backlinks de 2.076 direcciones IP distintas.
Popularidad en Facebook
(Poco importante)
Esta página tiene 0 compartir y comentarios en Facebook.

Backlinks desde Wikipedia

Descubre más links en la función de búsqueda de Wikipedia

Robots.txt

User-agent: *
Disallow: /wp-admin/
Allow: /wp-admin/admin-ajax.php
Disallow: /wp-includes/
Allow: /wp-includes/js/
Allow: /wp-includes/images/
Disallow: /trackback/
Disallow: /wp-login.php
Disallow: /wp-register.php
Disallow: /?s=*

Sitemap: https://www.ipsen.com/sitemap_index.xml

Páginas similares

Snippet (vista previa de los resultados de búsqueda)

www.ipsen.com
Ipsen Global - A Biopharmaceutical Company | Innovation for Patient...
Ipsen is a global biopharmaceutical company focused on innovation and specialty care to improve the lives of patients around the world.

Palabras clave más importantes

Se han encontrado las siguientes palabras clave. Comprueba si esta página está bien optimizada para cada palabra clave en concreto.

Palabra claveResultadoComprobar
Ipsen81%Check
Ipsen global71%Check
Global63%Check
Patients60%Check
biopharmaceutical58%Check
Biopharmaceutical Company58%Check
Global Biopharmaceutical Company58%Check
Ipsen Way58%Check
Company56%Check
innovation56%Check
Mostrar más palabras clave

¡Analiza ya gratis hasta 1.000 páginas de ipsen.com!

Registrarme Gratis
Puedes usar la suscripción Básica por tiempo ilimitado.

Política de cookies

Utilizamos cookies para el buen funcionamiento de nuestra web y con fines analíticos y publicitarios. Puedes activar o desactivar las cookies opcionales. Para más información consulta los siguientes enlaces.

Aviso legal | Privacidad y Cookies

Utilizamos estas cookies para que el sitio funcione correctamente

Con estas cookies podemos entender mejor cómo navegan las y los visitantes por nuestra web

Estas cookies nos ayudan a ofrecerte anuncios y promociones que se ajusten a tus intereses